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Abstract
Background: P. aeruginosa chronically colonizes the
lung in CF patients and elicits a proinflammatory
response. Excessive secretion of IL-6 and IL-8 by
CF airway cells in response to P. aeruginosa infection
in the CF airway is though to contribute to lung injury.
Accordingly, the goal of this study was to test the
hypothesis that Corr4a and VRT325, investigational
compounds that increase ΔF508-CFTR mediated
Cl- secretion in human CF airway cells, reduce the
pro-inflammatory response to P. aeruginosa. Methods:
IL-6 and IL-8 secretion by polarized CF human airway
epithelial cells (CFBE41o-) were measured by
multiplex analysis, and ΔF508-CFTR Cl- secretion
was measured in Ussing chambers. Airway cells were
exposed to P. aeruginosa (PAO1 or PA14) and
Corr4a or VRT325. Results: Corr4a and VRT325
increased ΔF508-CFTR Cl- secretion but did not
reduce either constitutive IL-6 or IL-8 secretion, or
IL-6 and IL-8 secretion stimulated by P. aeruginosa
(PA14 or PAO1). Conclusions: Corr4a and VRT325
do not reduce the inflammatory response to
Introduction
Cystic Fibrosis (CF), one of the most common lethal
genetic disorders in Caucasians, is an autosomal recessive
disorder caused by mutations in the CFTR gene [1-3].
The most common mutation in CFTR, ΔF508, results in
the degradation of CFTR by the proteasome. Thus, unlike
wt-CFTR, ΔF508-CFTR is unable to reach the apical
plasma membrane and mediate Cl- secretion. Accordingly,
CF is characterized by abnormal CFTR mediated Cl-
secretion in affected tissues including the lung, pancreas,
gastrointestinal tract, liver, and sweat glands. Reduced
Cl- and fluid secretion in the lung, hyperabsorption of
sodium together with an increased viscosity of mucus all
contribute to reduced mucociliary clearance of bacteria
from the lung of CF patients [4-6]. Chronic bacterial
infection primarily by P. aeruginosa and an exacerbated
and prolonged hyper-inflammatory response result in the
accumulation of neutrophils in the CF airways, which is
responsible for lung injury and the morbidity and mortality
in CF [7, 8].
P. aeruginosa in  human cystic fibrosis airway epithelial
cells.
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Close to 80% of CF patients are colonized by highly
drug resistant strains of Pseudomonas aeruginosa by
the age of 16 [7, 8]. P. aeruginosa induces an intense
proinflammatory response in the CF lung, which is
characterized by an increase in cytokine secretion, notably
IL-6 and IL-8 [9-12]. These proinflammatory cytokines,
as well as many others, play an important role in the innate
immune response to P. aeruginosa infection by recruiting
macrophages and neutrophils into the lung, which are
critical for reducing the bacterial burden.
Recently, a major effort among CF researchers has
been to identify drugs to correct defective trafficking of
ΔF508-CFTR and increase Cl- secretion. A number of
investigational compounds have been identified that
increase the expression of ΔF508-CFTR in the apical
plasma membrane of human airway epithelial cells, and
at least partially restore CFTR mediated Cl- secretion.
Notably, Corr4a and VRT325 increase the cell surface
expression of ΔF508-CFTR and stimulate CFTR mediated
Cl- secretion [13, 14]. Although identification of these and
other compounds to correct defective CFTR Cl- secretion
is promising, there is little information regarding the effects
of these compounds on other phenotypic changes in CF.
Ideally, the most efficacious drug for CF patients would
enhance ΔF508-CFTR mediated Cl- secretion, reduce the
excessive proinflammatory response of airway cells and
reduce the bacterial burden in the lungs. Recently, we
showed that Corr4a reduced the ability of P. aeruginosa
to form antibiotic resistant biofilms on CF airway epithelial
cells [15]. However, the effect of Corr4a and VRT325
on the proinflammatory response to P. aeruginosa has
not been reported. Thus, goal of this study was to test the
hypothesis that Corr4a and VRT325 reduce P.
aeruginosa stimulated IL-6 and IL-8 secretion by human
CF airway epithelial cells. We report that Corr4a and
VRT325 did not reduce either constitutive IL-6 or IL-8
secretion, or IL-6 and IL-8 secretion stimulated by P.
aeruginosa (PA14 or PAO1). Thus, Corr4a and VRT325
do not reduce the inflammatory response to P.




CFBE41o- (Cystic Fibrosis Bronchial Epithelial cells, clone
41o-) cells homozygous for the ΔF508 mutation were originally
isolated from a CF patient by Dr. D. Gruenert [16, 17]. Cells were
propagated in tissue polystyrene culture flasks in MEM
supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml
streptomycin, and 2 mM L-glutamine. For cytokine assays and
Ussing chamber studies cells were seeded on 12 mm diameter
collagen-coated semi-permeable polycarbonate membranes (0.4
µm pore size; Corning Corporation; Corning, NY) at 5 x 105 cells
per filter and grown in air-liquid interface at 37°C for 7-10 days
to develop polarized monolayers. The media was replaced on
the basolateral side of the membranes every 24 hours. To
synchronize cells they were serum-starved for the last 24 hours
in culture before experiments.
Drug Treatment
The Cystic Fibrosis Foundation Therapeutics Inc.
provided Corr4a and VRT325 and stocks were prepared in
DMSO. Corr4a (5 or 10 µM) was added to both apical and
basolateral sides of cells for 24 hours and then to the basolateral
side only for an additional 24 hours. VRT325 (3.3 or 6.7 µM)
was added to both apical and basolateral side for 24 hours and
then to the basolateral side only for an additional 72 hours.
DMSO (vehicle) was added to control cells. These treatment
protocols were similar to those published previously and
shown to produce a submaximal (lower dose for each
compound) or maximal (higher dose for each compound)
stimulatory effect on CFTR Cl transport [13, 14].
Transepithelial current measurements
Studies were conducted to confirm that VRT325 and
Corr4a enhance ΔF508-CFTR Cl- secretion in CFBE41o- cells.
Polarized monolayers of CFBE41o- cells grown on 12-mm-
diameter permeable membrane supports as described above
were mounted in an Ussing-type chamber (Physiological
Instruments, San Diego, CA) and bathed in solutions that were
maintained at 37°C and pH 7.4 and stirred using bubbling with
5% CO2-95% air. The apical bath solution contained 5 mM NaCl,
115 mM sodium gluconate, 25 mM NaHCO3, 3.3 mM KH2PO4,
0.8 mM K2HPO4, 1.0 mM MgCl2, 1.0 mM CaCl2, and 10 mM
mannitol. The basolateral bath solution contained 120 mM
NaCl, 25 mM NaHCO3, 3.3 mM KH2PO4, 0.8 mM K2HPO4, 1.0
mM MgCl2, 1.0 mM CaCl2, and 10 mM glucose. Short-circuit
current (Isc) was measured by clamping the transepithelial
voltage across the monolayers to 0 mV by using a voltage
clamp (model VCC MC6; Physiological Instruments) as
described previously [18-20]. In previous studies we
demonstrated that the genistein (50 µM) stimulated and CFTR-
172 inhibited current across CFBE41o- cells was mediated by
ΔF508-CFTR [19-20]. Thus, the ΔF508-CFTR Cl- current reported
in Figure 1 represents the genistein (50 µM) stimulated Isc that
is inhibited by CFTR-172. Current output from the clamp was
digitized using an analog-to-digital converter (iWorx, Dover,
NH). Data collection and analysis were performed using
LabScribe software, version 1.8 (iWorx).
Bacteria
A recent clinical isolate of P. aeruginosa, PA14, and PAO1,
a standard laboratory strain of P. aeruginosa, were kindly
provided by Dr. George O’Toole in the Department of
Microbiology and Immunology at Dartmouth Medical School.
PA14 and PAO1 cultures were grown in LB medium at 37oC on
a shaker for 18 hours to 5X109 CFU per ml. Bacteria were
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centrifuged and the pellet was washed twice with MEM. 2X108
CFU of PA14 or PAO1 were added to the apical side of polarized
monolayers of CFBE41o- cells for one hour at 37°C. Thereafter,
monolayers were washed twice with serum-free MEM
containing 100 µg/ml gentamicin and subsequently were
incubated with fresh serum-free MEM containing gentamicin
on both apical (100 µl) and basolateral sides (1.5 ml) at 37°C for
24 hours. 24 hours after monolayers were treated with PA14 or
PAO1 the supernatant was collected from the apical side of the
monolayers, centrifuged to eliminate cellular debris, and stored
at -80°C until IL-6 and IL-8 levels were measured. Preliminary
studies revealed that this treatment protocol (CFU and time of
exposure) produced a maximal effect on cytokine secretion with
minimal damage to airway epithelial cells.
Multiplex cytokine assays
IL-6 and IL-8 were measured using a Bio-Plex human
cytokine multiplex ELISA assay (Bio-Rad, Hercules, CA).
Calibration curves from recombinant cytokine standards were
prepared with threefold dilution steps in the same matrix as the
culture supernatants (RPMI 1640 medium containing 10% FBS).
High and low spikes (supernatants from stimulated human
dendritic cells) were included to determine cytokine recovery.
Standards and spikes were measured in triplicate, samples were
measured once, and blank values were subtracted from all
readings. All assays were carried out directly in a 96-well
filtration plate (Millipore, Billerica, MA) at room temperature
and protected from light. Briefly, wells were pre-wetted with
100 µl PBS containing 1% BSA. Beads together with a standard,
sample, spikes, or blank were added in a final volume of 100 µl,
and incubated together at room temperature for 30 min with
continuous shaking. Beads were washed three times with 100
µl PBS containing 1% BSA and 0.05% Tween 20. A cocktail of
biotinylated antibodies (IL-6 or IL-8; 50 µl /well) was added to
beads for a further 30 min incubation with continuous shaking.
Beads were washed three times, and incubated with
streptavidin-PE for 10 min. Beads were again washed three
times and resuspended in 125 µl of PBS containing 1% BSA
and 0.05% Tween 20. The fluorescence intensity of the beads
was measured in using the Bio-Plex array reader. Bio-Plex
Manager software with five-parametric-curve fitting (Bio-Rad
technical note 2861 at www.bio-rad.com) was used for data
analysis.
Statistical Analysis
Data were analyzed using Graphpad Prism statistical
software version 4.0b and reported as mean ± SEM. Statistical
differences between means were compared by one-way ANOVA
with Dunnett’s post-test using GraphPad Prism (GraphPad
Software, San Diego, CA, www.graphpad.com).
Results
Corr4a and VRT325 stimulate ΔF508-CFTR Cl-
secretion in CFBE41o- cells
The goal of this study was to test the hypothesis
that Corr4a and VRT325, investigational compounds that
increase ΔF508-CFTR mediated Cl- secretion in CF
airway cells, reduces the pro-inflammatory response to
P. aeruginosa. To confirm that Corr4a and VRT325
enhance ΔF508-CFTR mediated Cl- secretion in
CFBE41o- cells we conducted Ussing chamber studies.
Ussing chamber studies on polarized CFBE41o- cells
grown as confluent monolayers in an air-liquid interface
culture confirmed that Corr4a and VRT325 increase Cl-
secretion (Figure 1). These results are comparable to data
reported by other laboratories in several different cell lines
and in primary airway cells [13, 14, 21, 22], and indicate
that these cells lines are an excellent model to test our
hypothesis that VRT325 and Corr4a, by increasing
ΔF508-CFTR mediated Cl- secretion, reduce the pro-
inflammatory response to P. aeruginosa.
Corr4a does not reduce basal or P. aeruginosa
simulated IL-6 and IL-8 secretion by CFBE41o-
cells
Studies were conducted to test the hypothesis that
Corr4a reduces P. aeruginosa simulated IL-6 and IL-8
secretion by CFBE41o- cells. To this end airway cells
were grown in air-liquid interface culture and treated with
vehicle (DMSO) or Corr4a as described in Methods. P.
aeruginosa (PA14 or PAO1) were added to the apical
side of polarized CFBE41o- (homozygous for ΔF508/
ΔF508) cells for 1 hour. Subsequently, PA14 or PAO1
were removed by extensive washing with PBS, and the
airway cells were cultured for an additional 24 hours in
air liquid interface culture in MEM containing gentamicin.
IL-6 secretion was measured using a Bio-Plex ELISA
assay, as described in Methods.
Corr4a (5 or 10 µM) had no effect on constitutive
IL-6 secretion by CFBE41o- cells (Figure 2). As expected
PA14 and PAO1 increased IL-6 secretion by CFBE41o-
cells treated with vehicle (Figure 2). However, Corr4a (5
or 10 µM) did not reduce the ability of PA14 and PAO1
Fig. 1. VRT325 and Corr4a increased the short circuit Cl- current
mediated by ΔF508-CFTR. Controls treated with DMSO, the
vehicle for the drugs. *P<0.01 versus DMSO. n=5-6/group.
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to stimulate IL-6 secretion (Figure 2). Thus, Corr4a did
not reduce the proinflammatory response to P.
aeruginosa (PA14 or PAO1) as determined by measuring
IL-6 secretion.
Similar experiments were conducted to examine the
effect of Corr4a on IL-8 secretion by polarized CFBE41o-
cells. Corr4a (5 or 10 µM) had no effect on constitutive
IL-8 secretion (Figure 3). Moreover, Corr4a (5 or 10 µM)
did not reduce the ability of PA14 or PAO1 to stimulate
IL-8 secretion by CFBE41o- cells (Figure 3). Thus,
Corr4a did not reduce the proinflammatory response to
P. aeruginosa (PA14 or PAO1) as determined by
measuring IL-8 secretion.
VRT325 does not reduce basal or P. aeruginosa
simulated IL-6 and IL-8 secretion by CFBE41o-
cells
Similar experiments were conducted to test the
hypothesis that VRT325 reduces basal and P. aeruginosa
induced IL-6 secretion by CFBE41o- cells. VRT325 (3.3
or 6.7 µM) had no effect on constitutive IL-6 secretion.
Moreover, VRT325 (3.3 or 6.7 µM) did not reduce the
ability of PA14 or PAO1 to stimulate IL-6 secretion by
CFBE41o- cells (Figure 4). Thus, VRT325 did not reduce
the proinflammatory response to P. aeruginosa (PA14
Fig. 2. Corr4a had no effect on
constitutive IL-6 secretion (compare
Control with +Corr4a (5 and 10 μM)) or
on the increase in IL-6 secretion in cells
exposed to PA14 (2A: compare +PA14
with both +PA14 + Corr4a groups) or
PAO1 (2B: compare +PAO1 with both
+PAO1 + Corr4a groups). *P<0.05 versus
Control. n=6/group. NS, indicates no
statistical difference among these three
experimental groups.
Fig. 3. Corr4a had no effect on
constitutive IL-8 secretion (compare
Control with +Corr4a (5 and 10 µM)) or
on the increase in IL-8 secretion in
monolayers exposed to PA14 (3A:
compare +PA14 with both +PA14 +
Corr4a groups) or PAO1 (3B: compare
+PAO1 with both +PAO1 + Corr4a
groups). *P<0.05 versus Control. n=6/
group. NS, indicates no statistical
difference among these three
experimental groups.
or PAO1) as determined by measuring IL-6 secretion.
Finally, studies were also conducted to examine the
effect of VRT325 on IL-8 secretion by CFBE41o- cells.
VRT325 had no effect on constitutive IL-8 secretion
(Figure 5). Moreover, VRT325 did not reduce the ability
of PA14 or PAO1 to stimulate IL-8 secretion (Figure 5).
In fact, VRT (6.7 µM) elicited a statistically significant
increase in IL-8 production in cells exposed to PAO1
compared to cells exposed to PAO1 alone (Figure 5).
Thus, VRT325 did not reduce the proinflammatory
response to P. aeruginosa as determined by measuring
IL-8 secretion.
Discussion
The major new finding in this study is that neither
Corr4a nor VRT325, investigational compounds that
stimulate ΔF508-CFTR Cl- secretion in polarized human
CF airway epithelial cells, reduced either constitutive or
P. aeruginosa (PA14 and PAO1) stimulated IL-6 and
IL-8 secretion. We focused on IL-6 and IL-8 secretion
because numerous studies have shown that their secretion
by airway cells is enhanced by P. aeruginosa [9, 23-27]
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Fig. 4. VRT325 had no effect on constitutive IL-6
secretion (compare Control with +VRT325 (3.3 and 6.7
µM)) or on the increase in IL-6 secretion in monolayers
exposed to PA14 (4A: compare +PA14 with both +PA14
+ VRT325 groups) or PAO1 (4B: compare +PAO1 with
both +PAO1 + VRT325 groups). *P<0.05 versus Control.
n=6/group. NS, indicates no statistical difference among
these three experimental groups.
Fig. 5. VRT325 had no effect on constitutive IL-8
secretion (compare Control with both +VRT325 groups)
or on the increase in IL-8 secretion in monolayers
exposed to PA14 (5A: compare +PA14 with both +PA14
+ VRT325 groups. NS, indicates no statistical difference
among these three experimental groups.). Although the
3.3 µM dose of VRT325 had no effect on the PAO1-
induced increase in IL-8 secretion, the 6.7 µM dose
increased PAO1-stimulated IL-8 secretion (5B: compare
+PAO1 with +PAO1 + 6.7 µM VRT325. # over the
horizontal line indicates that +PAO1 is significantly
different from PAO1 + 6.7 µM VRT325 (P<0.05)). *P<0.05
versus control.
response to P. aeruginosa is though to contribute to
morbidity and mortality in CF.
Chemical rescue of ΔF508-CFTR Cl- secretion by
other compounds changes IL-8 secretion. For example,
MPB-07 (benz(c)quinolizinium), increases ΔF508-CFTR
Cl- secretion in IB3-1 and CuFi-1 CF cells and decreases
P. aeruginosa (PAO1) stimulation of IL-8 secretion by
an unknown mechanism [28]. Moreover, 8-cyclopentyl-
1,3-dipropylxanthine (CPX), which increases
ΔF508-CFTR Cl- secretion in IB3-1 CF cells, reduces
constitutive IL-8 secretion, but enhances IL-8 secretion
in response to a clinical isolate of P. aeruginosa [25].
Taken together with the present studies these data
illustrate the clinically relevant point that experimental
drugs that correct ΔF508-CFTR trafficking and
Cl- secretion do not all have similar effects on constitutive
or stimulated (by P. aeruginosa) cytokine secretion.
The most effective drugs for CF patients would ideally
enhance ΔF508-CFTR Cl- secretion and reduce the
proinflammatory response.
The inability of Corr4a and VRT325 to reduce basal
or P. aeruginosa stimulated IL-6 and IL-8 secretion by
CF human airway epithelial cells suggests that they are
not optimal drugs for CF patients since elevated levels of
cytokines in the CF airway contribute to lung injury [29].
A major goal in CF research is to develop a treatment
or a cure for this pernicious disease. As drug candidates
are identified and developed it is essential to evaluate the
effects of these therapeutic agents on ΔF508-CFTR
Cl- secretion as well as on other pathological changes
that occur in CF including the ability of P. aeruginosa to
colonize the lung, hypersecretion of mucus, enhanced
sodium reabsorption, and secretion of proinflammatory
cytokines. To this end in a previous study we demonstrated
that Corr4a reduced the ability of P. aeruginosa to form
antibiotic resistant biofilms on CFBE41o- cells [15].
However, in the present study we demonstrated that,
unfortunately, neither Corr4a nor VRT325 reduced either
constitutive or stimulated (P. aeruginosa) IL-6 and IL-8
secretion.
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